Immuneering highlighted enrollment in its global Phase 3 MAPKeeper 301 trial testing atebimetinib with chemotherapy in first-line metastatic pancreatic cancer.
Clinical results were already presented from an earlier Phase 2a study, supporting the Phase 3 strategy in newly diagnosed metastatic patients.
The Phase 2a outcome indicated longer survival with generally manageable safety, with the most serious side effects largely tied to chemotherapy.
Management framed the latest FDA clearance in second-line pancreatic cancer as a milestone, shifting competitive focus toward first-line treatment development.
IMRX•
